Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company - - Added late-stage pediatric onset rare disease asset, protein kinase C β isoform
Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
(0)
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications
Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue disorder resulting in high morbidity and a significantly shortened life span with no FDA-approved treatments
Rumpus co-founders Christopher Brooke and Nathaniel Massari to join Aytu executive team with responsibility for AR101 program and development of pediatric onset rare disease pipeline
Company to host conference call today at 4:30 PM ET
ENGLEWOOD, CO / ACCESSWIRE / April 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the acquisition of a global license to AR101 (enzastaurin), a pivotal study-ready therapeutic candidate initially targeting the treatment of vascular Ehlers-Danlos Syndrome (vEDS) f
Press release content from Accesswire. The AP news staff was not involved in its creation.
Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
April 12, 2021 GMT
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indicationsProgram initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue .
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indicationsProgram initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue .
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications